MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma

Human Molecular Genetics

Volumn 22, Issue 5, 2013, Pages 904-918

  Costa, Pedro M ^a,b   Cardoso, Ana L ^a   Nóbrega, Clévio ^a   Pereira de almeida, Luís F ^a,c   Bruce, Jeffrey N ^d   Canoll, Peter ^e   Pedroso de Lima, Maria C ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d Department of Neurosurgery   (Colombia)

^e Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; MICRORNA; MICRORNA 128; MICRORNA 21; OLIGONUCLEOTIDE; PDCD4 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIFITHRIN ALPHA; SUNITINIB; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INDOLES; MICE; MICRORNAS; PTEN PHOSPHOHYDROLASE; PYRROLES; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84873438180     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds496     Document Type: Article

References (65)

1. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U. et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352, 987-996.
2. Khasraw, M. and Lassman, A.B. (2010) Advances in the treatment of malignant gliomas. Curr. Oncol. Rep., 12, 26-33.
3. Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J., Janzer, R.C., Ludwin, S.K., Allgeier, A., Fisher, B., Belanger, K. et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 10, 459-466.
4. Bartel, D.P. and Chen, C.Z. (2004) Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet., 5, 396-400.
5. Guo, H., Ingolia, N.T., Weissman, J.S. and Bartel, D.P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 466, 835-840.
6. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
7. Esquela-Kerscher, A. and Slack, F.J. (2006) Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259-269.
8. Calin, G.A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S.E., Iorio, M.V., Visone, R., Sever, N.I., Fabbri, M. et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med., 353, 1793-1801.
9. Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M. et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA, 103, 2257-2261.
10. Ciafre, S.A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.G., Sabatino, G., Negrini, M., Maira, G., Croce, C.M. and Farace, M.G. (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun., 334, 1351-1358.
11. Hank, N.C., Shapiro, J.R. and Scheck, A.C. (2006) Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. BMC Cancer, 6, 2.
12. Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P. et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110.
13. Ohgaki, H. and Kleihues, P. (2007) Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol., 170, 1445-1453.
14. Lena, A., Rechichi, M., Salvetti, A., Bartoli, B., Vecchio, D., Scarcelli, V., Amoroso, R., Benvenuti, L., Gagliardi, R., Gremigni, V. et al. (2009) Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J. Transl. Med., 7, 13.
15. Prados, M.D., Lamborn, K.R., Chang, S., Burton, E., Butowski, N., Malec, M., Kapadia, A., Rabbitt, J., Page, M.S., Fedoroff, A. et al. (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro. Oncol., 8, 67-78.
16. Lawler, S. and Chiocca, E.A. (2009) Emerging functions of microRNAs in glioblastoma. J. Neurooncol., 92, 297-306.
17. Silber, J., Lim, D.A., Petritsch, C., Persson, A.I., Maunakea, A.K., Yu, M., Vandenberg, S.R., Ginzinger, D.G., James, C.D., Costello, J.F. et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med., 6, 14.
18. Godlewski, J., Nowicki, M.O., Bronisz, A., Williams, S., Otsuki, A., Nuovo, G., Raychaudhury, A., Newton, H.B., Chiocca, E.A. and Lawler, S. (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res., 68, 9125-9130.
19. Morris, P.G. and Abrey, L.E. (2010) Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas. Target Oncol., 5, 193-200.
20. Lei, L., Sonabend, A.M., Guarnieri, P., Soderquist, C., Ludwig, T., Rosenfeld, S., Bruce, J.N. and Canoll, P. (2011) Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One, 6, e20041.
21. Chan, J.A., Krichevsky, A.M. and Kosik, K.S. (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res., 65, 6029-6033.
22. Conti, A., Aguennouz, M., La Torre, D., Tomasello, C., Cardali, S., Angileri, F.F., Maio, F., Cama, A., Germano, A., Vita, G. et al. (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J. Neurooncol., 93, 325-332.
23. Network, C.G.A.R. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
24. Selcuklu, S.D., Donoghue, M.T. and Spillane, C. (2009) miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans., 37, 918-925.
25. Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S. and Mo, Y.Y. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res., 18, 350-359.
26. Trabulo, S., Resina, S., Simoes, S., Lebleu, B. and Pedroso de Lima, M.C. (2010) A non-covalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. J. Control Release, 145, 149-158.
27. Lu, Z., Liu, M., Stribinskis, V., Klinge, C.M., Ramos, K.S., Colburn, N.H. and Li, Y. (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 27, 4373-4379.
28. Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T. and Patel, T. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-658.
29. Papagiannakopoulos, T., Shapiro, A. and Kosik, K.S. (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res., 68, 8164-8172.
30. Ak, P. and Levine, A.J. (2010) p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. FASEB J, 24, 3643-3652.
31. Stiewe, T. (2007) The p53 family in differentiation and tumorigenesis. Nat. Rev. Cancer, 7, 165-168.
32. Kim, S., Han, J., Lee, S.K., Hur, S.M., Koo, M., Cho, D.H., Bae, S.Y., Choi, M.Y., Shin, I., Yang, J.H. et al. (2010) Pifithrin-alpha, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway. Pharmacology, 86, 313-319.
33. Murphy, P.J., Galigniana, M.D., Morishima, Y., Harrell, J.M., Kwok, R.P., Ljungman, M. and Pratt, W.B. (2004) Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J. Biol. Chem., 279, 30195-30201.
34. Fan, S., Qi, M., Yu, Y., Li, L., Yao, G., Tashiro, S., Onodera, S. and Ikejima, T. (2012) P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK. Free Radic. Res., 46, 310-319.
35. Strosznajder, R.P., Jesko, H., Banasik, M. and Tanaka, S. (2005) Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress. J. Physiol. Pharmacol., 56(Suppl. 4), 215-221.
36. Rocha, S., Campbell, K.J., Roche, K.C. and Perkins, N.D. (2003) The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro. BMC Mol. Biol., 4, 9.
37. Tergaonkar, V. and Perkins, N.D. (2007) p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol. Cell, 26, 158-159.
38. Ben-Neriah, Y. and Karin, M. (2011) Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol., 12, 715-723.
39. Gabriely, G., Wurdinger, T., Kesari, S., Esau, C.C., Burchard, J., Linsley, P.S. and Krichevsky, A.M. (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell Biol., 28, 5369-5380.
40. Heinzelmann, J., Henning, B., Sanjmyatav, J., Posorski, N., Steiner, T., Wunderlich, H., Gajda, M.R. and Junker, K. (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J. Urol., 29, 367-373.
41. Zhang, H., Li, Y. and Lai, M. (2010) The microRNA network and tumor metastasis. Oncogene, 29, 937-948.
42. Asangani, I.A., Rasheed, S.A., Nikolova, D.A., Leupold, J.H., Colburn, N.H., Post, S. and Allgayer, H. (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene, 27, 2128-2136.
43. Zhu, S., Si, M.L., Wu, H. and Mo, Y.Y. (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem., 282, 14328-14336.
44. Gaur, A.B., Holbeck, S.L., Colburn, N.H. and Israel, M.A. (2011) Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro. Oncol., 13, 580-590.
45. Lino, M.M. and Merlo, A. (2010) PI3Kinase signaling in glioblastoma. J. Neurooncol., 103, 417-427.
46. Zhou, X., Ren, Y., Moore, L., Mei, M., You, Y., Xu, P., Wang, B., Wang, G., Jia, Z., Pu, P. et al. (2010) Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab. Invest., 90, 144-155.
47. Gao, F., Zhang, P., Zhou, C., Li, J., Wang, Q., Zhu, F., Ma, C., Sun, W. and Zhang, L. (2007) Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol. Rep., 17, 123-128.
48. Yang, H.S., Jansen, A.P., Komar, A.A., Zheng, X., Merrick, W.C., Costes, S., Lockett, S.J., Sonenberg, N. and Colburn, N.H. (2003) The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol., 23, 26-37.
49. Yang, H.S., Jansen, A.P., Nair, R., Shibahara, K., Verma, A.K., Cmarik, J.L. and Colburn, N.H. (2001) A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene, 20, 669-676.
50. Goke, R., Barth, P., Schmidt, A., Samans, B. and Lankat-Buttgereit, B. (2004) Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am. J. Physiol. Cell Physiol., 287, C1541-C1546.
51. Chen, Y., Liu, W., Chao, T., Zhang, Y., Yan, X., Gong, Y., Qiang, B., Yuan, J., Sun, M. and Peng, X. (2008) MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett., 272, 197-205.
52. Corsten, M.F., Miranda, R., Kasmieh, R., Krichevsky, A.M., Weissleder, R. and Shah, K. (2007) MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res., 67, 8994-9000.
53. Ren, Y., Kang, C.S., Yuan, X.B., Zhou, X., Xu, P., Han, L., Wang, G.X., Jia, Z., Zhong, Y., Yu, S. et al. (2010) Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J. Biomater. Sci. Polym. Ed., 21, 303-314.
54. Ren, Y., Zhou, X., Mei, M., Yuan, X.B., Han, L., Wang, G.X., Jia, Z.F., Xu, P., Pu, P.Y. and Kang, C.S. (2010) MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer, 10, 27.
55. Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N., Michotte, A. et al. (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol., 103, 491-501.
56. Banker, G. and Goslin, K. (1998) Culturing Nerve Cells, 2nd edn. pp. 499-542. The MIT Press, Cambridge, MA.
57. de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P. and Deglon, N. (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci., 22, 3473-3483.
58. Alves, S., Nascimento-Ferreira, I., Dufour, N., Hassig, R., Auregan, G., Nobrega, C., Brouillet, E., Hantraye, P., Pedroso de Lima, M.C., Deglon, N. et al. (2010) Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum. Mol. Genet., 19, 2380-2394.
59. Cardoso, A.L., Guedes, J.R., Pereira de Almeida, L. and Pedroso de Lima, M.C. (2012) miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology, 135, 73-88.
60. Lee, H., Choi, H.J., Kang, C.S., Lee, H.J., Lee, W.S. and Park, C.S. (2012) Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Mod. Pathol., 25, 1508-1515.
61. Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res., 29, e45.
62. Ferreira, R., Xapelli, S., Santos, T., Silva, A.P., Cristovao, A., Cortes, L. and Malva, J.O. (2010) Neuropeptide Y modulation of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in microglia. J. Biol. Chem., 285, 41921-41934.
63. Pena, J.T., Sohn-Lee, C., Rouhanifard, S.H., Ludwig, J., Hafner, M., Mihailovic, A., Lim, C., Holoch, D., Berninger, P., Zavolan, M. et al. (2009) miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat. Methods, 6, 139-141.
64. O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem., 267, 5421-5426.
65. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. B, 57, 289-300.